Achieve Life Sciences Announces $25 Million Loan Facility from Silicon Valley Bank to Fund Cytisinicline Smoking Cessation Clinical DevelopmentGlobeNewsWire • 12/22/21
Achieve Life Sciences to Host Key Opinion Leader Panel on Smoking and e-Cigarette CessationGlobeNewsWire • 11/23/21
Achieve Life Sciences Announces Phase 3 ORCA-2 Trial of Cytisinicline in Smoking Cessation Clears Final Review by Data Safety Monitoring Committee (DSMC)GlobeNewsWire • 11/22/21
Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/10/21
Achieve Reports Financial Results for Third Quarter 2021 and Provides Update on Cytisinicline DevelopmentGlobeNewsWire • 11/09/21
Achieve Life Sciences Announces Participation in November Investor ConferencesGlobeNewsWire • 11/04/21
Achieve Life Sciences To Start Cytisinicline's Trial For Nicotine E-cigarette CessationBenzinga • 11/02/21
Achieve Life Sciences to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 9, 2021GlobeNewsWire • 10/26/21
Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 21st Annual Society for Research on Nicotine & Tobacco (SRNT-E) Virtual ConferenceAccesswire • 09/14/21
Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement AwardsAccesswire • 08/13/21
Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/13/21
Achieve Reports Financial Results for Second Quarter 2021 and Provides Corporate UpdateAccesswire • 08/11/21
Achieve Announces Two Patents Granted by USPTO for Novel Cytisinicline Dosing and Administration RegimenAccesswire • 08/11/21
Achieve Life Sciences to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 12, 2021Accesswire • 08/03/21
Achieve Life Sciences Awarded Grant from the National Institutes of Health (NIH) for the Evaluation of Cytisinicline in Cessation of Nicotine E-cigarette UseAccesswire • 07/22/21
Achieve Announces Completion of Target Enrollment of 750 Subjects in Phase 3 ORCA-2 Smoking Cessation Trial of CytisiniclineAccesswire • 06/29/21
Achieve Announces Allowance of U.S. Patents for Dosing and Administration of Cytisinicline for the Treatment and Prevention of AddictionAccesswire • 06/03/21
Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesAccesswire • 05/27/21
Achieve Life Sciences Announces Pricing of $20 Million Underwritten Public OfferingAccesswire • 05/25/21